Investment Rating - The investment rating for the company is "Buy" [2][6]. Core Insights - The company recorded a total revenue of RMB 6.29 billion in 2025, a year-on-year decrease of 4.6%, while brands La Koradior and FUUNNY FEELLN continued to show double-digit growth [3]. - The gross profit margin remained high at 76.6%, with a year-on-year decrease in net profit attributable to shareholders of 15.3% to RMB 400 million, and a dividend of HKD 0.35 per share was declared [3]. - The company is focusing on channel optimization, reducing the total number of stores to 1,739, with a strategy to close inefficient small stores and increase the proportion of larger stores in quality shopping centers and outlets [3]. - E-commerce sales grew by 12.0% year-on-year, accounting for 21.6% of total revenue, with a shift towards brand expression and member operations in online sales [4]. - Inventory levels remain high but have slightly improved, with the proportion of finished goods decreasing to 86% [4]. Summary by Sections Financial Performance - In 2025, total revenue was RMB 6,285.8 million, with a projected increase to RMB 6,483.0 million in 2026, reflecting a growth rate of 3.1% [12]. - The gross profit for 2025 was RMB 4,812.3 million, maintaining a gross profit margin of 76.6% [12]. - Net profit attributable to shareholders for 2025 was RMB 397.0 million, with projections of RMB 424.4 million for 2026 [12]. Market Position and Strategy - The company is adjusting its distribution strategy by potentially increasing discounts for distributors and expanding their regional coverage, with small-scale trials planned for 2026 [4]. - The company aims for stable growth and improved store efficiency while optimizing channel structure, despite not making adjustments for short-term fluctuations [5]. Valuation and Price Target - The target price has been adjusted to HKD 10.66 per share, reflecting a longer recovery time [5]. - The current share price is HKD 6.58, with a 52-week range of HKD 6.18 to HKD 10.98 [6].

Investment Rating - The report maintains a "Buy" rating for RoboSense (02498.HK) with a target price of HKD 46.10, adjusted from a previous target of HKD 48.50 [2][4][7]. Core Insights - RoboSense achieved a revenue of RMB 7.57 billion in Q4 2025, representing a year-on-year growth of 46.1%. This quarter also marked the company's first-ever profit, indicating a significant operational turnaround driven by the benefits of its digital product platform, cost reductions from in-house chip development, and an optimized revenue mix [3][7]. - The company is expected to see substantial growth in the shipment of its ADAS (Advanced Driver Assistance Systems) LiDAR products, particularly with the introduction of new models EMX and EM4, which are anticipated to replace older models and drive demand in 2026 [6][7]. - The report highlights three key growth catalysts for 2026: continued growth in ADAS LiDAR, expansion in the robotics sector, and sustained profitability despite competitive pricing pressures [7]. Financial Summary - Revenue projections for RoboSense are as follows: RMB 1,941 million for 2025, RMB 3,472 million for 2026, RMB 4,498 million for 2027, and RMB 5,484 million for 2028, indicating a significant growth trajectory [10]. - Gross profit is expected to increase from RMB 514.2 million in 2025 to RMB 1,530.2 million by 2028, with gross margins projected to remain relatively stable between 20% and 25% for ADAS LiDAR products [10][11]. - The company reported a net profit of RMB 55.9 million for 2026, a significant turnaround from a loss of RMB 145.0 million in 2025, with further growth expected in subsequent years [10][11].

Investment Rating - The report assigns a "BUY" rating to RoboSense (02498.HK) with a target price of HK$ 48.50 per share [2][7]. Core Insights - RoboSense reported strong Q4 2025 operating metrics, achieving breakeven in the quarter due to significant increases in LiDAR shipments for both ADAS and robotics [3][7]. - The robotics segment, particularly lawn mower robots, was a key driver of growth, supported by product upgrades and new customer additions [4]. - Demand for new digital LiDAR products, EMX and EM4, is expected to exceed expectations, contributing significantly to revenue in 2026 [5]. - Technological advancements showcased at CES, including a Delivery Assistant robot, highlight RoboSense's innovation capabilities [6]. - The upward revision of sales volume forecasts and revenue assumptions reflects stronger-than-expected demand, leading to improved gross margin forecasts [7]. Financial Overview - For 2025, RoboSense is projected to generate revenue of RMB 2,019.6 million, with a gross profit of RMB 557.9 million and a gross margin of 27.6% [8]. - The company anticipates a significant increase in revenue to RMB 4,002.8 million by 2026, with a gross profit of RMB 1,142.1 million [8]. - The financial metrics indicate a path to profitability, with net profit expected to turn positive by 2026, reaching RMB 221.6 million [8].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HK$ 48.50 [2][5]. Core Insights - The company achieved a breakeven point in Q4 2025, driven by strong operational performance, with ADAS lidar sales reaching 238,400 units (up 54.8% year-on-year) and robotic lidar sales soaring to 221,200 units (up 2,565.1% year-on-year) [2][5]. - The growth in robotic lidar sales is primarily attributed to the demand for lawnmower robots, with expectations for continued growth due to product upgrades and new customer acquisitions [3]. - The new digital lidar products EMX (192 lines) and EM4 (>500 lines) are expected to become major revenue sources in 2026, gradually replacing older models [4]. - The company showcased advanced technology at CES, including a delivery robot capable of performing nearly 20 complex tasks, enhancing its product matrix with new lidar products [5]. Financial Summary - Revenue projections for the company are as follows: RMB 1,648.9 million for 2024, RMB 2,019.6 million for 2025, RMB 4,002.8 million for 2026, and RMB 5,147.3 million for 2027, reflecting a growth rate of 47.2% in 2024 and 22.5% in 2025 [13]. - Gross profit is expected to increase from RMB 283.6 million in 2024 to RMB 1,445.4 million in 2027, with gross margins improving from 17.2% to 28.1% over the same period [13]. - The company anticipates a net profit of RMB 221.6 million in 2026 and RMB 421.9 million in 2027, following a loss of RMB 481.8 million in 2024 and a reduced loss of RMB 239.2 million in 2025 [6][13].

Investment Rating - The report assigns a "Buy" rating to Shanghai Baoji Pharmaceutical with a target price of HK$ 111.30 [2][6]. Core Insights - Shanghai Baoji Pharmaceutical (02659.HK) is a biotechnology company focused on developing and providing recombinant biopharmaceuticals using synthetic biology technology, targeting complex diseases with limited treatment options [3][12]. - The company has established a product pipeline consisting of one approved drug and seven candidates in clinical stages, along with four preclinical assets [3][12]. - The company aims to address the pain points of traditional pharmaceuticals by producing biopharmaceuticals that can replace biochemical extraction products derived from animal organs, blood, or urine [5][12]. Business Overview - The company is currently focused on four strategic therapeutic areas: i) large-volume subcutaneous administration, ii) antibody-mediated autoimmune diseases, iii) assisted reproductive drugs, and iv) other recombinant bioproducts [3][12]. - The company has a clear commercialization model and timeline, expecting significant revenue contributions starting in 2026 from its core products KJ017 and SJ02, with KJ103 anticipated to contribute from 2027 [4][12]. Product Development - KJ017, a key product, is a highly glycosylated recombinant hyaluronidase designed for subcutaneous drug delivery, expected to receive NDA approval in Q1 2026 [8][22]. - KJ103, a recombinant IgG degrading enzyme, is the only product of its kind expected to be launched in China, targeting autoimmune diseases and transplant desensitization [8][31]. - SJ02, a long-acting recombinant FSH product, has been approved for marketing and is expected to significantly improve patient outcomes in assisted reproduction [39][40]. Financial Projections - The company forecasts revenues of HK$ 6.9 million in 2024, increasing to HK$ 530 million by 2027, with a gross margin projected to decline from 97.8% in 2024 to 82.7% in 2027 [6][10]. - The company is expected to incur net losses in the coming years, with projected losses of HK$ 160.4 million in 2024 and HK$ 30.8 million in 2027 [6][10]. Market Position - The company has a first-mover advantage in China for its core products, which have already been commercialized in some foreign markets, indicating a strong market demand [4][12]. - The company has established partnerships with other pharmaceutical and biotechnology firms to develop subcutaneous drug delivery solutions, enhancing its market presence [26][29].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HK$ 43.50 [2][4]. Core Insights - In 2024, the company is expected to achieve a revenue growth of 47.2%, reaching RMB 1.648 billion, with 93.0% of revenue derived from sales of lidar used in ADAS, robotics, and other applications [2][3]. - The gross margin for 2024 is projected to improve significantly to 17.2%, while the net loss is expected to narrow to RMB 480 million [2][4]. - The company plans to offer customizable solutions to meet diverse customer needs, particularly in the automotive market, where there is a higher demand for cost-performance balance [4]. Revenue and Financial Performance - The company’s revenue for 2024 is projected at RMB 1,648.9 million, with a year-on-year growth of 47.2% [10]. - The gross profit is expected to be RMB 283.6 million, with a gross margin of 17.2% [10]. - The net loss for 2024 is anticipated to be RMB 481.8 million, improving in subsequent years to a profit of RMB 446.1 million by 2026 [10]. Market Position and Competitive Landscape - The company maintains a strong R&D capability, allowing it to adapt to market trends and provide competitive solutions [4]. - The lidar market for ADAS remains highly concentrated, which helps OEMs maintain balance and mitigate supply chain risks [4]. - The sales volume of lidar for ADAS in Q4 2024 is reported at 153,900 units, with expectations for gradual growth despite increased competition [3]. Product Development and Future Outlook - The company has over 100 models with mass production orders as of March 31, 2025, indicating strong market penetration [3]. - The recently launched EM4 lidar, featuring 1080 lines and a detection range of 600 meters, enhances the product portfolio [3]. - The company is optimistic about the growth of lidar shipments for robotics, with a sales target of 8,300 units in Q4 2024 [3].

Investment Rating - The report assigns a "BUY" rating to RoboSense (02498.HK) with a target price of HK$ 43.50 [2][6]. Core Insights - RoboSense reported a year-on-year revenue increase of 47.2%, reaching RMB 1,648.9 million in 2024, with 93.0% of revenue coming from LIDAR sales for ADAS, robotics, and other applications [2][6]. - The gross margin improved significantly to 17.2%, while the net loss narrowed to RMB 481.8 million [2][6]. - The company is well-positioned to maintain its leadership in the LiDAR sector, with expectations of achieving break-even by 2026 [6]. Revenue and Growth - Revenue for 2024 was RMB 1,648.9 million, with projected revenues of RMB 2,502.7 million in 2025, RMB 3,425.3 million in 2026, and RMB 5,199.2 million in 2027 [7][13]. - The year-on-year growth rates are projected at 51.8% for 2025, 36.9% for 2026, and 51.8% for 2027 [13]. Product Performance - In Q4 2024, RoboSense sold 153,900 units of LIDAR for ADAS, with the M1P model being the primary revenue driver, while the MX model is expected to gain traction [4][6]. - The company achieved sales of 8,300 units of LIDAR for robotics in Q4 2024, with growth anticipated from the E1R model and other new models [5][6]. Market Position and Strategy - RoboSense's strong R&D capabilities allow it to adapt to market trends and offer competitive solutions, focusing on customizable solutions for diverse applications [6]. - The ADAS LiDAR market is characterized by concentration and oligopoly, enabling OEMs to mitigate concentration risks effectively [6]. Financial Metrics - The gross profit for 2024 was RMB 283.6 million, with a gross margin of 17.2% [13][14]. - The report indicates a projected improvement in gross margin to 21.6% in 2025 and 24.9% in 2026 [13][14].

Investment Rating - The report does not provide a specific investment rating for the company [4] Core Insights - The company is expected to achieve a turnaround and consider dividend distribution once its related business becomes profitable [2][98] - The acquisition of BTHL has increased the company's stake to 70%, enhancing its revenue and cash flow sources [2][12] - A fare adjustment of 7.5% for city and New Territories routes has been approved, effective January 5, 2025, which is anticipated to positively impact profitability [2][90] Business Overview - The company, through its subsidiary Glorify, acquired approximately 54.44% of BTHL for HK$ 2.72 billion, raising its ownership to 70% [2][12] - BTHL focuses on providing public bus and tourism-related services under the Citybus brand and is the exclusive advertising agent for Citybus vehicle advertising [2][12] - The merger of Citybus and Newbus is expected to optimize routes, enhance operational efficiency, and reduce costs [3][7] Financial Data and Peer Comparison - BTHL generated total revenue of HK$ 34.9 billion in 2023, accounting for 78.6% of the group's total revenue [98] - The company has a market capitalization of approximately HK$ 1 billion, with a potential dividend yield of 6% to 7% based on a 95% profit distribution [2][98] - The financial performance of the bus industry improved significantly in 2023, with a recovery in passenger numbers post-pandemic [98][101] Industry Overview - The Hong Kong public bus industry consists of both franchised and non-franchised bus services, with franchised buses serving areas not easily accessible by rail [60] - The number of franchised bus routes in Hong Kong increased from 670 in 2018 to 750 in 2023, with Citybus operating 233 routes [60][92] - The industry size was approximately HK$ 10.64 billion in 2023, with Citybus holding a market share of about 27.9% [92][93]

Investment Rating - The report does not provide a specific investment rating for the company [4] Core Insights - The company, Hans Group Holdings (00554.HK), has acquired an additional 54.44% stake in BTHL for HK$ 2.72 billion, increasing its ownership to 70% [2][12] - The acquisition is expected to lead to a turnaround and potential dividend distribution, with a 7.5% fare increase approved for Citybus routes, effective January 5, 2025, which is anticipated to have a minimal impact on demand [2][98] - The merger of Citybus and New World First Bus is expected to enhance operational efficiency and reduce costs through route optimization and resource sharing [3][7] Business Overview - The acquisition of BTHL is valued at approximately HK$ 5.0 billion, with HK$ 500 million paid in cash and HK$ 220 million in shares [12] - BTHL focuses on providing public bus and tourism-related services in Hong Kong, as well as advertising services [13] - Citybus operates 233 franchised bus routes, with a fleet of 1,495 licensed buses, primarily serving the Hong Kong Island area [23] Financial Data and Peer Comparison - In 2023, BTHL generated total revenue of HK$ 3.49 billion, accounting for 78.6% of the group's total revenue [98] - The company reported a net loss of HK$ 73.6 million in 2023, with an operating profit margin of 3.4% [101] - The financial performance of the franchised bus industry improved significantly in 2023, with a recovery in passenger numbers post-pandemic [101] Industry Overview - The Hong Kong franchised bus industry is projected to reach a market size of approximately HK$ 10.64 billion in 2023, with Citybus holding a market share of about 27.9% [92] - The number of franchised bus routes in Hong Kong increased from 670 in 2018 to 750 in 2023, with Citybus routes growing from 205 to 233 [60] - The report highlights that the demand for franchised bus services remains relatively inelastic, suggesting that fare increases will not significantly affect ridership [98]

Investment Rating - The report assigns a stock rating of NR (Not Rated) for Hans Group Holdings Limited (00554.HK) [6] Core Insights - The acquisition of 54.44% of BTHL by Hans Group for HKD 2.7 billion increases its stake to 70%, with BTHL valued at approximately HKD 5 billion [4][15] - A fare adjustment of 7.5% for Citybus routes is expected to help the company return to profitability by increasing revenue without significantly impacting demand [5][90] - The potential for dividend distribution exists if Citybus achieves net profit, with a possible yield of 6% to 7% based on a 95% payout ratio [5][90] Business Overview - BTHL provides public bus services under the Citybus brand, including advertising and tourism services [4][15] - The company operates a fleet of 1,495 buses across 233 routes, with a significant increase in passenger numbers post-pandemic [25][26][68] Financial Performance - BTHL reported total revenue of HKD 34.9 billion in 2023, a 35.1% increase year-on-year, with ticket revenue contributing 87.3% of total income [26][46] - The company aims to improve operational efficiency and reduce costs through the merger with NWFB, which is expected to optimize routes and enhance resource utilization [7][97] Industry Overview - The Hong Kong franchised bus industry is dominated by four operators, with Citybus being the sole operator for routes on Hong Kong Island [58] - The industry faced challenges during the pandemic but is recovering, with a projected market size of HKD 10.6 billion in 2023 [86] Investment Thesis - The anticipated fare increase and potential for dividend distribution are key factors for investment consideration, as Citybus is the main revenue source for Hans Group [90] - The merger with NWFB is expected to create synergies and improve financial performance through cost savings and operational efficiencies [97]